Lab-grown 'mini guts' bring personalised IBD treatment for children a step closer
核心洞察
Researchers from Monash University and the Hudson Institute of Medical Research have created the first organoid models combining a patient's intestinal lining with their own gut bacteria to study inflammation.
The 'mini guts' allow scientists to test how individual patients' bacteria drive inflammation, moving beyond a 'one-size-fits-all' approach toward personalised IBD treatment.
The team has built a living biobank of matched organoids and bacterial collections from paediatric Australian patients, laying groundwork for testing tailored interventions before they reach the bedside.
Researchers from Monash University and the Hudson Institute of Medical Research have grown live models of paediatric patients' digestive systems to investigate solutions for inflammatory bowel disease (搜索) (IBD). Using live tissue and bacteria from the intestine to create miniature 3D 'organoid' models — nicknamed 'mini guts' — the team has been able to test how and where the specific bacteria in a patient's digestive system can affect tissue and cause inflammation.
Published in Scientific Reports, part of the Nature suite of journals, this research is the first to have developed an organoid model that incorporates both the intestinal lining and its bacteria, and pioneers the technology to inject bacteria into the intestinal organoids to study its impact on inflammation.
A step toward personalised IBD treatment
Lead researcher Professor Helen Abud, from the Monash Biomedicine Discovery Institute, said the work takes researchers a step closer to personalised IBD treatments. "The mini guts we have developed allow us to move past a 'one-size-fits-all' approach," Professor Abud said. "By creating living replicas of a patient's intestinal lining, we can observe how this critical barrier protects the body from harmful gut contents, and how it heals or breaks down when exposed to different bacteria."
She added: "These mini-guts organise themselves exactly like a real bowel lining, providing a beautiful and accurate tool for understanding the diversity of this disease."
The microbiome is unique to each person, which means an IBD treatment that works for one person may not work for another. This individuality is central to the clinical challenge the researchers aim to address.
Clinical significance for children
Senior researcher Adjunct Associate Professor Edward Giles, a researcher at Monash University and the Hudson Institute of Medical Research and paediatric gastroenterologist at Monash Children's Hospital, said the approach has the potential to significantly improve care for children with IBD.
"Children aged 9 to 18 represent a group where early intervention is vital, as they face decades of managing this chronic condition," Associate Professor Giles said. "From a clinical perspective, this methodology is unique because it combines the expert study of a patient's disease with the specific bacteria living at the site of their inflammation."
He added: "It gives us a way to test whether we can promote healing of the intestinal barrier or even find 'protective' bacteria that could become treatments themselves."
A predictive research tool
First author Dr Eva Chan, from the Innate Immune Responses to Infection Research group in the Centre for Innate Immunity and Infectious Diseases at the Hudson Institute of Medical Research, framed the work as more than disease modelling.
"This methodology isn't just about recreating a disease state, it's about developing a predictive research tool," Dr Chan said. "By building this biobank of matched organoids and bacterial collection from each individual patient, we are laying the groundwork for a future where we can test and tailor interventions in the lab before they ever reach the patient's bedside."
The team has created a "living bio bank" of several different organoids, based on several different patients. "The overall goal is to find the best treatment for each individual patient so we need to have a replica of a whole diversity of individual patients," Professor Abud said. "And this patient population is from our local paediatric Australian patients, so it's going to be relevant to patients that are being treated here."
The burden of IBD
Ulcerative colitis (搜索) is one of the two major types of inflammatory bowel disease (搜索), the other being Crohn's disease (搜索). It is marked by inflammation and ulceration in the large intestine, causing at times painful and debilitating gastrointestinal symptoms. There is no cure, but it can be managed with medication.
IBD is estimated to affect about 180,000 Australians, and for reasons experts are not yet able to explain, that number is on the rise. By about 2030, the number of sufferers will amount to 1 per cent of the population.
The statistics are alarming for advocates such as Leanne Raven, the chief executive at Crohn's and Colitis Australia. "In Australia, the prevalence and the incidence is just compounding," Ms Raven said. "We are worried because there are so many barriers to people getting diagnosed and then getting into remission."
She said a recent study by her organisation found that, of all chronic conditions, IBD had the lowest investment in research. "Being able to use technology to play around and test different things and see what response you get is fantastic, really innovative work," she said. "Research is our hope for the future."
Expert perspective and limitations
Australian National University School of Medicine and Psychology Emeritus Professor Paul Pavli described the research as "exciting". "It is a very important study. It's meticulous work, it's painstaking and it's going to provide very valuable insight into the cause of some of these diseases," he said.
Dr Pavli, who also works as a consultant in gastroenterology at Canberra Hospital, said the work would enable medical professionals and researchers to understand the basic mechanisms of how the bacteria and the lining of the gut cause inflammation, and could lead to personalised medical care. "This is leading towards personalised medicine where you can actually identify the things that go wrong that cause inflammatory bowel diseases in such patients," Dr Pavli said.
He cautioned, however, that clinical translation will take time. "It's not something that's going to develop in the next two or three years or even five years. It's going to take some time to develop the techniques to be able to provide any sort of personalised medicine."
Dr Pavli also noted that the field has historically received limited funding. "Crohn's and colitis are not sexy diseases," he said. "These conditions are quite serious conditions affecting young people significantly and anything that provides some insight into what goes wrong is going to lead to better treatments."